Compare SPRY & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRY | CYPH |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.8M | 321.1M |
| IPO Year | 2020 | 2019 |
| Metric | SPRY | CYPH |
|---|---|---|
| Price | $3.05 | $2.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 11.3M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,278,000.00 | $1,500,000.00 |
| Revenue This Year | $52.57 | N/A |
| Revenue Next Year | $45.52 | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.91 | $0.49 |
| 52 Week High | $13.15 | $4.19 |
| Indicator | SPRY | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.39 | 45.48 |
| Support Level | N/A | $2.22 |
| Resistance Level | $4.55 | $3.35 |
| Average True Range (ATR) | 0.28 | 0.42 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 8.82 | 18.95 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.